CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

Home About What We Do Programs and Services CADTH Reimbursement Review ataluren

ataluren

Last Updated: March 5, 2019

Result type: Reports

Project Number: SR0607-000

Product Line: Reimbursement Review

Generic Name: ataluren

Brand Name: Translarna

Manufacturer: PTC Therapeutics Canada ULC

Indications: Dystrophinopathy

Manufacturer Requested Reimbursement Criteria¹:

For the treatment of dystrophinopathy resulting from a nonsense mutation in the dystrophin gene.

Submission Type: Initial

Project Status: Cancelled

Biosimilar: No

Fee Schedule: Pending

The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.